INBRX-101
Alpha-1 Antitrypsin Deficiency (AATD)
Key Facts
About Inhibrx Biosciences
Inhibrx leverages its proprietary sdAb platform to create differentiated, multi-specific protein therapeutics designed to overcome the limitations of conventional antibodies. The company's pipeline includes multiple clinical-stage assets targeting oncology and rare diseases, with strategic partnerships in place with major pharmaceutical companies. Inhibrx's approach focuses on optimizing pharmacokinetics, tissue penetration, and manufacturability to develop best-in-class therapies for complex biological targets.
View full company profileTherapeutic Areas
Other Alpha-1 Antitrypsin Deficiency (AATD) Drugs
| Drug | Company | Phase |
|---|---|---|
| BEAM-302 | Beam Therapeutics | Preclinical |
| WVE-006 | WaVe Life Sciences | Phase 1/2 |
| Glassia® (IV AAT) | Kamada | Approved |
| Inhaled AAT (KMA-001) | Kamada | Phase 3 |
| GalNAc Program (SERPINA1 target) | Korro Bio | Discovery |
| Unnamed AATD Program | AlveoGene | Pre-clinical |